LexaGene Announces Multi-System Purchase from a Large Market Leader in Animal Health
May 25 2022 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a molecular diagnostics company that
has commercialized an instrument for automated multiplex PCR
testing, is pleased to announce a large veterinary animal health
corporation has purchased 2 MiQLab® Systems for two of their
locations. Both locations will use the MiQLab Systems for fast
evidence-based decision making at the point of care.
The MiQLab System is designed for in-clinic use, requires less
than a minute to initiate sample processing, and returns results on
the presence of 10 different pathogens and 33 markers for
antimicrobial resistance in just 2 hours.
Dr. Jack Regan, LexaGene’s CEO and Founder stated, “A month ago,
we announced our first multi-system purchase into one of the three
major references laboratories servicing the veterinary industry.
Today, we announced our first multi-system purchase into a large
veterinary corporation that owns over 100 specialty and emergency
pet hospitals and clinics across the United States. We believe that
our technology will add sufficient value to their business to
justify a more aggressive adoption of the MiQLab System throughout
their organization.”
He continued, “When a new business-disrupting technology is
introduced to a Company of this size, it often takes many months to
present the advantages of the technology to the Company’s key
decision making committee. We are encouraged that this market
leader has interest in our technology and shares our belief that
fast, accurate diagnostic testing at the point of care is critical
for animal health and required for better antimicrobial
stewardship. This sale further boosts our momentum in veterinary
diagnostics.”
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab® system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
For inquiries: 800.215.1824 | ir@lexagene.com or info@lexagene.com
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024